iRhythm Technologies Announces Chief Financial Officer Transition
iRhythm Technologies (NASDAQ: IRTC) announced a leadership transition in its finance department. Brice Bobzien, the current CFO, will step down on August 31, 2024, for personal reasons. He will be succeeded by Daniel Wilson, the company's Executive Vice President of Corporate Development and Investor Relations. Bobzien, who has served as CFO since 2022, will continue in an advisory role into 2025 to ensure a smooth transition.
CEO Quentin Blackford praised Bobzien's contributions in transforming iRhythm's finance organization and positioning the company for growth. Wilson, who has been with iRhythm since 2019, brings extensive experience in corporate development, strategy, and investor relations. His background includes roles at Penumbra, J.P. Morgan, and Piper Jaffray, focusing on healthcare and medical technology sectors.
iRhythm Technologies (NASDAQ: IRTC) ha annunciato una transizione della leadership nel suo dipartimento finanziario. Brice Bobzien, l'attuale CFO, si dimetterà il 31 agosto 2024 per motivi personali. Sarà succeduto da Daniel Wilson, attuale vicepresidente esecutivo dello sviluppo aziendale e delle relazioni con gli investitori. Bobzien, che ricopre il ruolo di CFO dal 2022, continuerà a dare consulenze fino al 2025 per garantire una transizione fluida.
Il CEO Quentin Blackford ha lodato i contributi di Bobzien nella trasformazione dell'organizzazione finanziaria di iRhythm e nel posizionamento dell'azienda per la crescita. Wilson, presente in iRhythm dal 2019, porta con sé una vasta esperienza nello sviluppo aziendale, nella strategia e nelle relazioni con gli investitori. Il suo bagaglio professionale include ruoli in Penumbra, J.P. Morgan e Piper Jaffray, con focus sui settori della salute e della tecnologia medica.
iRhythm Technologies (NASDAQ: IRTC) anunció una transición en el liderazgo de su departamento financiero. Brice Bobzien, el actual CFO, dejará su puesto el 31 de agosto de 2024, por razones personales. Será sucedido por Daniel Wilson, actual vicepresidente ejecutivo de desarrollo corporativo y relaciones con inversionistas de la compañía. Bobzien, quien ha sido CFO desde 2022, continuará en un papel de asesor hasta 2025 para asegurar una transición fluida.
El CEO Quentin Blackford elogió las contribuciones de Bobzien en la transformación de la organización financiera de iRhythm y en el posicionamiento de la empresa para el crecimiento. Wilson, quien ha estado en iRhythm desde 2019, aporta una amplia experiencia en desarrollo corporativo, estrategia y relaciones con inversionistas. Su trayectoria incluye roles en Penumbra, J.P. Morgan y Piper Jaffray, centrándose en los sectores de salud y tecnología médica.
iRhythm Technologies (NASDAQ: IRTC)는 재무 부서의 리더십 전환을 발표했습니다. 현재 CFO인 Brice Bobzien은 개인적인 사유로 2024년 8월 31일에 사임할 예정입니다. 그는 회사의 기업 개발 및 투자자 관계를 담당하고 있는 Daniel Wilson에게 자리를 넘길 것입니다. 2022년부터 CFO로 재직 중인 Bobzien은 원활한 인수인계를 위해 2025년까지 자문 역할을 계속할 것입니다.
CEO인 Quentin Blackford는 Bobzien의 기여가 iRhythm의 재무 조직을 전환하고 회사의 성장 가능성을 확보하는 데 도움을 주었다고 평가했습니다. 2019년부터 iRhythm에서 근무해온 Wilson은 기업 개발, 전략 및 투자자 관계 분야에서 폭넓은 경험을 가지고 있습니다. 그는 Penumbra, J.P. Morgan 및 Piper Jaffray에서 의료 및 의료 기술 분야에 중점을 둔 역할을 수행했습니다.
iRhythm Technologies (NASDAQ: IRTC) a annoncé une transition de leadership dans son département financier. Brice Bobzien, l'actuel CFO, quittera son poste le 31 août 2024 pour des raisons personnelles. Il sera remplacé par Daniel Wilson, vice-président exécutif du développement d'entreprise et des relations avec les investisseurs de la société. Bobzien, en poste en tant que CFO depuis 2022, continuera à jouer un rôle de conseil jusqu'en 2025 pour assurer une transition en douceur.
Le PDG Quentin Blackford a salué les contributions de Bobzien pour la transformation de l'organisation financière d'iRhythm et le positionnement de l'entreprise pour la croissance. Wilson, présent chez iRhythm depuis 2019, apporte une vaste expérience en développement d'entreprise, en stratégie et en relations avec les investisseurs. Son parcours professionnel comprend des rôles chez Penumbra, J.P. Morgan et Piper Jaffray, se concentrant sur les secteurs de la santé et de la technologie médicale.
iRhythm Technologies (NASDAQ: IRTC) hat einen Führungswechsel in seiner Finanzabteilung bekannt gegeben. Brice Bobzien, der derzeitige CFO, wird aus persönlichen Gründen zum 31. August 2024 zurücktreten. Sein Nachfolger wird Daniel Wilson sein, der derzeitige Executive Vice President für Unternehmensentwicklung und Investor Relations des Unternehmens. Bobzien, der seit 2022 CFO ist, wird bis 2025 weiterhin in beratender Funktion tätig sein, um einen reibungslosen Übergang zu gewährleisten.
CEO Quentin Blackford lobte die Beiträge von Bobzien, die Finanzorganisation von iRhythm zu transformieren und das Unternehmen für Wachstum zu positionieren. Wilson, der seit 2019 bei iRhythm ist, bringt umfangreiche Erfahrungen in den Bereichen Unternehmensentwicklung, Strategie und Investor Relations mit. Sein beruflicher Hintergrund umfasst Rollen bei Penumbra, J.P. Morgan und Piper Jaffray, wobei der Schwerpunkt auf den Bereichen Gesundheitswesen und Medizintechnologie liegt.
- Smooth leadership transition planned with current CFO staying on in advisory role
- New CFO Daniel Wilson brings extensive experience in healthcare and finance sectors
- Wilson's familiarity with iRhythm since 2019 suggests continuity in financial strategy
- Departure of current CFO Brice Bobzien after only two years in the role
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition.
“Brice has been an outstanding leader at iRhythm over the past two years, making significant contributions to transform iRhythm’s finance organization during his tenure with the company,” said Quentin Blackford, iRhythm’s President and CEO. “He has been invaluable in helping position our company to operate efficiently and effectively ahead of immense growth, leading with a disciplined and rigorous approach to financial management, operational excellence, and strategic development. We wish him all the best as he shifts his attention towards personal and family matters.”
“At the same time, we are thrilled to have Dan take over the finance organization and are confident in the expanded leadership he will provide as our next CFO. Dan has a long history with iRhythm, advising the company on its initial public offering and then joining iRhythm in 2019. In his time with the company, Dan has been a trusted partner, strategic leader, unwavering brand ambassador, and a passionate champion of iRhythm’s mission. His strong strategic background, industry experience, and financial acumen make him uniquely qualified to help lead the organization into our next phase of growth.”
Mr. Wilson has served as iRhythm’s Executive Vice President of Corporate Development and Investor Relations since April 2023 and previously served as Executive Vice President of Corporate Development, Corporate Strategy, and Investor Relations since June 2019. Previously, he served as Director and Head of Business Development at Penumbra, Inc., a global healthcare company focused on innovative therapies. Prior to Penumbra, he held various positions at J.P. Morgan between August 2006 and May 2016, most recently as Executive Director in the Healthcare Investment Banking group focused on digital health, medical technology, and emerging healthcare companies. Earlier in his career, he held various positions in Piper Jaffray’s Healthcare Investment Banking group. He started his career at KPMG as an Audit Associate. Mr. Wilson has a B.S. in Business Administration from California Polytechnic State University at San Luis Obispo.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact
Stephanie Zhadkevich
investors@irhythmtech.com
Media Contact
Kassandra Perry
irhythm@highwirepr.com
FAQ
When will Brice Bobzien step down as CFO of iRhythm Technologies (IRTC)?
Who will succeed Brice Bobzien as CFO of iRhythm Technologies (IRTC)?
What is Daniel Wilson's background before joining iRhythm Technologies (IRTC)?
How long has Brice Bobzien served as CFO of iRhythm Technologies (IRTC)?
